Introduction: Pharmacogenetics is the study of variations in DNA sequence as related to drug response (European Medicines Agency [EMA], 2007). Several gene-drug interactions have been discovered in the field of cardiovascular diseases (CVDs). These gene-drug interactions can help to identify nonresponse to drugs, estimate dose requirements or identify an increased risk of developing adverse drug reactions. An individualized approach based on pharmacogenetic testing will provide physicians and pharmacists with tools for decision making about pharmacotherapy. While pharmacogenetic testing is already part of everyday practice in oncology, it is not widely implemented in the field of CVDs. However, in the near future, pharmacogenetics will probably also play a valuable role in this field as well.

Additional Metadata
ISBN 978-953-51-0222-9
Persistent URL dx.doi.org/10.5772/2218, hdl.handle.net/1765/38360
Note In: Luca Gallelli (ed.), Pharmacology. InTech Publishers, March 14, 2012 under CC BY 3.0 license
Citation
van Schie, R.F.M, Verhoef, T.I, Maitland-van der Zee, A-H, de Boer, A.C, van der Meer, F.J.M, Redekop, W.K, & Thariani, R. (2012). Future of Pharmacogenetics in Cardiovascular Diseases. doi:10.5772/2218